Skip to content
Live
Trending storyPast story

Claude designed a scorpion venom-binding protein with unverified antitoxic effects.

2 reports2 outlets27 days agoUpdate

The story so far

AI overview

Investment research company Citrini partnered with Anthropic to design protein binders targeting scorpion neurotoxins for an unreleased Claude model, but failed to produce antitoxin. The model generated about 211 candidate protein designs, of which 17 could bind to four out of the five scorpion toxins set by the team. Citrini admitted that the experiment did not produce a drug, stating that the most innovative aspect was the 'autonomous discovery process rather than the biological outcome'. Anthropic stated that Claude completed the design autonomously within 24 hours after receiving the initial prompt, but it remains to be tested whether these protein binders can actually function as antitoxin. The experiment was conducted in Anthropic's office, where Anthropic relaxed restrictions and provided more advanced unreleased models, on the condition that the team work in their lab. Experts point out that the binding of candidate molecules to toxins is only an early stage of drug development, and converting it into an effective drug still faces huge challenges.

AI-written from the reports · Updated 27 days ago

Developments

2 developments

  1. 22 Oct, 20:21 · 1 reports
    Claude did not invent scorpion antivenom
    The Verge · AI:Claude did not invent scorpion antivenom
  2. 21 Oct, 16:37 · 1 reports
    Claude independently designed scorpion venom protein binders.
    The Decoder:Claude Science tackles deadly scorpion stings by designing protein binders from scratch

Coverage timeline

Follow the coverage to see every side of the story.

22 Oct
  1. The Verge · AI
    Claude did not invent scorpion antivenom

    Investment Research Company Citrini Collaborates with Anthropic to Try Generating Scorpion Antivenom Using an Unreleased Claude Model, Which Generated Approximately 211 Candidate Protein Designs, 17 of Which Can Bind to Part of Scorpion Toxin. Experts Point Out This is Only an Early Stage of Drug Development, and Converting Candidate Molecules into Effective Drugs Still Faces Huge Challenges. Citrini Admits the Experiment Did Not Successfully Create a Drug but States It Showcases the Potential of AI-Assisted Drug Discovery

21 Oct
  1. The DecoderFeatured
    Claude Science tackles deadly scorpion stings by designing protein binders from scratch

    Anthropic's Claude has essentially designed a protein complex targeting scorpion neurotoxins in the Claude Science research environment, a type of toxin that kills over 3250 people annually.